Artivion, Inc. SEC Filings

Artivion (AORT) reported third‑quarter 2025 results with total revenues of $113.4 million, up 18% year over year. Medical devices drove growth, led by aortic stent grafts $39.6 million (+38%) and On‑X $26.8 million (+25%), while preservation services contributed $25.7 million (+5%). Gross margin was $74.4 million, and operating income rose to $12.5 million.

Net income was $6.5 million (diluted EPS $0.13) versus a loss a year ago, aided by a $3.5 million PerClot sales milestone gain. Operating cash flow reached $20.3 million year to date, ending cash was $73.4 million. The company eliminated its $100.0 million Convertible Senior Notes via exchanges into ~4.35 million shares and small residual settlement, reducing interest expense. A credit amendment extended maturities to January 18, 2031 and lowered interest margins; total principal debt stood at $220.0 million with long‑term debt (net) of $214.9 million. Shares outstanding were 47,374,939 as of October 31, 2025.

Artivion, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is provided under Item 2.02 and is attached as Exhibit 99.1.

The company stated that the information is furnished, not filed, and is not incorporated by reference unless expressly noted. It also included forward‑looking statements subject to the Private Securities Litigation Reform Act safe harbor and directed readers to risk factors in its most recent Form 10‑K and subsequent filings.

BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of 5,977,264 shares of Artivion, Inc. (AORT) common stock, representing 12.7% of the class as of 09/30/2025.

BlackRock reports sole voting power over 5,912,256 shares and sole dispositive power over 5,977,264 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The interest of iShares Core S&P Small-Cap ETF in Artivion’s common stock is noted as more than five percent of outstanding shares.

Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc. (AORT), exercised stock options and sold an equal number of shares on 08/27/2025. He exercised a stock option with an $11.03 exercise price to acquire 18,200 shares and simultaneously sold 18,200 shares at a weighted average price of $44.023 per share. Following these transactions, Mr. Stanton beneficially owned 64,200 shares of Artivion common stock.

The option exercised had an original grant with a first exercisable date of 11/08/2023 and a stated vesting schedule of 33 1/3% per year. The filing notes the sale price range was $43.84 to $44.26 and that the reporting person can provide a breakdown of shares sold at each price upon request.

Artivion, Inc. (AORT) Form 144 discloses a proposed sale of 18,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $801,211.32. The shares were acquired and are listed for sale with an approximate sale date of 08/27/2025 following a stock option exercise paid in cash on the same date. The filing shows total shares outstanding of 47,183,658 and lists two prior sales by the same person in June 2025 of 15,000 and 26,132 shares, with gross proceeds of $442,500.00 and $743,129.66 respectively.

Jean F. Holloway, SVP & General Counsel of Artivion, Inc. (AORT), reported transactions on 08/25/2025. She exercised a stock option to acquire 10,000 shares at an exercise price of $11.03 per share and concurrently sold 10,000 shares at $44.37 per share. After these transactions she beneficially owned 172,129 shares. The option exercised relates to a grant with an $11.03 exercise price, originally exercisable beginning 11/08/2023 and expiring 11/08/2029; the option vests 33 1/3% per year starting on the first anniversary of the grant date.

Artivion, Inc. (AORT) Form 144 notice reports proposed sale of 10,000 common shares by an insider via Morgan Stanley Smith Barney LLC, with an aggregate market value of $443,700 and an approximate sale date of 08/25/2025. The form shows those shares were acquired and paid for on 08/25/2025 through a stock option exercise with cash payment. The filing also discloses two recent common-stock sales by JEAN F HOLLOWAY: 23,356 shares sold on 08/12/2025 for $1,004,605.97 and 8,748 shares sold on 05/27/2025 for $253,692.00. The filer affirms no undisclosed material adverse information.